-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $56

Benzinga·11/09/2026 11:28:32
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $55 to $56.